TDMS Study 05002-06 Pathology Tables
INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)
GAMMA-BUTYROLACTONE
NTP Experiment-Test: 05002-06 Report: PEIRPT05
Study Type: CHRONIC Date: 09/02/94
Route: GAVAGE Time: 19:44:38
Facility: Southern Research Institute
Chemical CAS #: 96-48-0
Lock Date: None
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05002-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC GAMMA-BUTYROLACTONE Date: 09/02/94
Route: GAVAGE Time: 19:44:38
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE VEHICLE 262. 525.
CONTROL MG/KG MG/KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50
Early Deaths
Moribund 8 11 9
Dead 4 5 3
Survivors
Terminal Sacrifice 38 34 38
Animals Examined Microscopically 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (47) (47)
Leiomyosarcoma, Metastatic, Mesentery 1 (2%)
Intestine Large, Colon (50) (1) (49)
Intestine Small, Duodenum (49) (49)
Leiomyosarcoma, Metastatic, Mesentery 1 (2%)
Polyp 1 (2%)
Intestine Small, Ileum (48) (1) (49)
Carcinoma 1 (2%)
Intestine Small, Jejunum (49) (49)
Liver (50) (50) (50)
Fibrosarcoma, Metastatic, Skin 1 (2%)
Hepatocellular Carcinoma 4 (8%) 2 (4%) 1 (2%)
Hepatocellular Adenoma 5 (10%) 3 (6%)
Mesentery (3) (5) (5)
Hemangiosarcoma 2 (40%) 1 (20%)
Leiomyosarcoma 1 (20%)
Pancreas (50) (50) (48)
Leiomyosarcoma, Metastatic, Mesentery 1 (2%)
Salivary Glands (50) (50)
Stomach, Forestomach (50) (49) (50)
Leiomyosarcoma, Metastatic, Mesentery 1 (2%)
Squamous Cell Papilloma 2 (4%) 5 (10%) 4 (8%)
Stomach, Glandular (50) (50) (50)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
None
____________________________________________________________________________________________________________________________________
Page 2
NTP Experiment-Test: 05002-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC GAMMA-BUTYROLACTONE Date: 09/02/94
Route: GAVAGE Time: 19:44:38
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE VEHICLE 262. 525.
CONTROL MG/KG MG/KG
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland, Cortex (50) (1) (50)
Spindle Cell, Adenoma 1 (2%)
Adrenal Gland, Medulla (50) (49)
Pheochromocytoma Malignant 1 (2%)
Pheochromocytoma Benign 1 (2%)
Islets, Pancreatic (50) (49) (47)
Adenoma 1 (2%) 2 (4%)
Carcinoma 1 (2%)
Pituitary Gland (48) (48) (43)
Pars Distalis, Adenoma 3 (6%) 5 (10%) 7 (16%)
Pars Intermedia, Adenoma 1 (2%)
Thyroid Gland (49) (48) (50)
Follicular Cell, Adenoma 3 (6%) 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Tissue NOS (1)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (48) (49) (46)
Cystadenoma 1 (2%) 1 (2%) 4 (9%)
Granulosa-Theca Tumor Malignant 1 (2%) 1 (2%)
Leiomyosarcoma, Metastatic, Mesentery 1 (2%)
Uterus (50) (41) (50)
Adenoma 1 (2%)
Carcinoma 2 (5%)
Deciduoma Benign 1 (2%)
Granulosa-Theca Tumor Malignant, Metastatic,
Ovary 1 (2%)
Hemangioma 1 (2%)
Hemangiosarcoma 1 (2%) 1 (2%)
Polyp Stromal 1 (2%) 1 (2%) 1 (2%)
Sarcoma Stromal 1 (2%) 1 (2%)
Vagina (2) (1)
Leiomyosarcoma 1 (50%)
Polyp 1 (50%)
____________________________________________________________________________________________________________________________________
Page 3
NTP Experiment-Test: 05002-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC GAMMA-BUTYROLACTONE Date: 09/02/94
Route: GAVAGE Time: 19:44:38
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE VEHICLE 262. 525.
CONTROL MG/KG MG/KG
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (50) (50)
Hemangiosarcoma 1 (2%)
Lymph Node (50) (6) (49)
Bronchial, Leiomyosarcoma, Metastatic,
Mesentery 1 (2%)
Mediastinal, Alveolar/Bronchiolar Carcinoma,
Metastatic, Lung 1 (17%)
Lymph Node, Mandibular (47) (1) (45)
Lymph Node, Mesenteric (49) (5) (43)
Spleen (50) (14) (50)
Thymus (47) (2) (44)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (50) (48) (50)
Carcinoma 2 (4%) 1 (2%) 1 (2%)
Skin (50) (47) (50)
Subcutaneous Tissue, Fibroma 1 (2%)
Subcutaneous Tissue, Fibrosarcoma 1 (2%) 3 (6%)
Subcutaneous Tissue, Hemangiosarcoma 1 (2%)
Subcutaneous Tissue, Schwannoma Benign 1 (2%)
Subcutaneous Tissue, Schwannoma Malignant 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (50) (50)
Osteosarcoma 1 (2%)
Skeletal Muscle (1) (4)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (25%)
Fibrosarcoma, Metastatic, Skin 1 (25%)
Hemangiosarcoma 1 (100%) 1 (25%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (50)
____________________________________________________________________________________________________________________________________
Page 4
NTP Experiment-Test: 05002-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC GAMMA-BUTYROLACTONE Date: 09/02/94
Route: GAVAGE Time: 19:44:38
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE VEHICLE 262. 525.
CONTROL MG/KG MG/KG
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50)
Alveolar/Bronchiolar Adenoma 5 (10%) 3 (6%) 3 (6%)
Alveolar/Bronchiolar Carcinoma 2 (4%) 1 (2%) 1 (2%)
Carcinoma, Metastatic, Harderian Gland 1 (2%) 1 (2%)
Carcinoma, Metastatic, Uterus 1 (2%)
Fibrosarcoma, Metastatic, Skin 1 (2%)
Granulosa-Theca Tumor Malignant, Metastatic,
Ovary 1 (2%)
Osteosarcoma, Metastatic, Bone 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (2) (43) (4)
Adenoma 1 (50%) 2 (5%) 3 (75%)
Carcinoma 1 (50%) 1 (25%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (50)
Fibrosarcoma, Metastatic, Skin 1 (2%)
Leiomyosarcoma, Metastatic, Mesentery 1 (2%)
Urinary Bladder (50) (1) (49)
Carcinoma, Metastatic, Uterus 1 (100%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50)
Lymphoma Malignant Histiocytic 1 (2%) 1 (2%)
Lymphoma Malignant Lymphocytic 2 (4%) 1 (2%) 1 (2%)
Lymphoma Malignant Mixed 8 (16%) 7 (14%) 8 (16%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 5
NTP Experiment-Test: 05002-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC GAMMA-BUTYROLACTONE Date: 09/02/94
Route: GAVAGE Time: 19:44:38
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE VEHICLE 262. 525.
CONTROL MG/KG MG/KG
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 33 31 35
Total Primary Neoplasms 50 48 51
Total Animals with Benign Neoplasms 17 21 25
Total Benign Neoplasms 23 23 31
Total Animals with Malignant Neoplasms 24 20 16
Total Malignant Neoplasms 27 25 20
Total Animals with Metastatic Neoplasms 4 3 3
Total Metastatic Neoplasm 4 8 9
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 6
NTP Experiment-Test: 05002-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC GAMMA-BUTYROLACTONE Date: 09/02/94
Route: GAVAGE Time: 19:44:38
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE VEHICLE 262. 525.
CONTROL MG/KG MG/KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50
Early Deaths
Moribund 13 8 23
Dead 2 12 12
Accident 1
Natural Death 1
Moribund Sacrifice 1
Survivors
Terminal Sacrifice 35 30 12
Animals Examined Microscopically 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Small, Jejunum (47) (45) (45)
Liver (50) (50) (50)
Hemangiosarcoma 2 (4%) 1 (2%)
Hepatocellular Carcinoma 16 (32%) 2 (4%) 8 (16%)
Hepatocellular Adenoma 8 (16%) 6 (12%) 1 (2%)
Pancreas (50) (49) (49)
Salivary Glands (48) (50) (48)
Fibrosarcoma, Metastatic, Skin 1 (2%)
Stomach, Forestomach (50) (49) (49)
Squamous Cell Papilloma 7 (14%) 2 (4%) 1 (2%)
Stomach, Glandular (50) (49) (49)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (50)
Hemangiosarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland, Cortex (48) (50) (50)
Adenoma 3 (6%) 3 (6%)
Spindle Cell, Adenoma 1 (2%)
Adrenal Gland, Medulla (48) (50) (50)
Pheochromocytoma Malignant 1 (2%) 1 (2%)
Pheochromocytoma Benign 1 (2%) 4 (8%) 1 (2%)
Bilateral, Pheochromocytoma Benign 1 (2%)
Islets, Pancreatic (50) (49) (48)
Adenoma 1 (2%)
Page 7
NTP Experiment-Test: 05002-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC GAMMA-BUTYROLACTONE Date: 09/02/94
Route: GAVAGE Time: 19:44:38
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE VEHICLE 262. 525.
CONTROL MG/KG MG/KG
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM - cont
Thyroid Gland (49) (50) (48)
Follicular Cell, Adenoma 1 (2%) 2 (4%) 2 (4%)
Follicular Cell, Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Tissue NOS (1) (1)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (50) (50) (49)
Prostate (49) (48) (48)
Fibrosarcoma, Metastatic, Skin 1 (2%)
Seminal Vesicle (8) (5) (9)
Testes (50) (50) (50)
Interstitial Cell, Adenoma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Blood (7) (2) (1)
Bone Marrow (50) (50) (49)
Lymph Node (50) (50) (49)
Inguinal, Hemangiosarcoma 1 (2%)
Lymph Node, Mandibular (45) (46) (46)
Lymph Node, Mesenteric (48) (46) (41)
Hemangiosarcoma 1 (2%)
Spleen (50) (50) (48)
Hemangiosarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (50) (50) (50)
Adenoma 1 (2%)
Basosquamous Tumor Benign 1 (2%)
Carcinoma 1 (2%)
Subcutaneous Tissue, Fibroma 1 (2%) 1 (2%)
Subcutaneous Tissue, Fibrosarcoma 9 (18%) 6 (12%) 6 (12%)
Subcutaneous Tissue, Hemangiosarcoma 1 (2%)
Subcutaneous Tissue, Lipoma 1 (2%)
Subcutaneous Tissue, Schwannoma Malignant 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
Page 8
NTP Experiment-Test: 05002-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC GAMMA-BUTYROLACTONE Date: 09/02/94
Route: GAVAGE Time: 19:44:38
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE VEHICLE 262. 525.
CONTROL MG/KG MG/KG
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Skeletal Muscle (1) (4) (2)
Schwannoma Malignant 1 (25%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
None
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50)
Alveolar/Bronchiolar Adenoma 10 (20%) 9 (18%) 6 (12%)
Hepatocellular Carcinoma, Metastatic, Liver 2 (4%) 1 (2%)
Nose (50) (50) (49)
Hemangiosarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (9) (48)
Adenoma 8 (89%) 1 (2%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (50)
Adenoma 1 (2%)
Urinary Bladder (50) (48) (48)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50)
Lymphoma Malignant Histiocytic 1 (2%) 1 (2%)
Lymphoma Malignant Lymphocytic 1 (2%)
Lymphoma Malignant Mixed 2 (4%) 2 (4%)
Lymphoma Malignant Undifferentiated Cell 1 (2%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 9
NTP Experiment-Test: 05002-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC GAMMA-BUTYROLACTONE Date: 09/02/94
Route: GAVAGE Time: 19:44:38
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE VEHICLE 262. 525.
CONTROL MG/KG MG/KG
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 40 31 23
Total Primary Neoplasms 77 48 33
Total Animals with Benign Neoplasms 25 26 12
Total Benign Neoplasms 41 31 15
Total Animals with Malignant Neoplasms 29 12 16
Total Malignant Neoplasms 36 17 18
Total Animals with Metastatic Neoplasms 3 2
Total Metastatic Neoplasm 3 2
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 10
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------